CXCR4 and acute myeloid leukemia: In the treatment of acute myeloid leukemia (AML), interrupting the connection between leukemic cells and the tumor microenvironment by targeting the stromal-derived factor-1α/CXCR4 (SDF-1α/CXCR4) axis has become an attractive approach [11, 12].